What is this medication?
Antineoplastic Agent, Cyclin-Dependent Kinase Inhibitor
Palbociclib, Ibrance is indicated for treatment of advanced breast cancer.
How does this medication work?
Palbociclib, Ibrance a cyclin-dependent kinase (CDK) inhibitor which is selective for CDK 4 and 6. Palbociclib, Ibrance inhibits the CD4/6 pathways which reduces proliferation of breast tumor cells by preventing progression from the G1 to the S cell cycle phase.
How should I take this medication?
Oral: 125mg daily for 21 days, then 7 days off.
How to Take:
Oral: Administer at approximately the same time each day. Swallow whole do not crush or chew; do not split tablets or open capsules prior to swallowing (do not ingest if tablets or capsules are broken, cracked, or not intact).
Tablets: Administer with or without food.
Capsules: Administer with food.
What should I watch for while using this medication?
Before starting Palbociclib, Ibrance make sure your physician is aware of any allergies or medications you currently take. Palbociclib, Ibrance has been known to cause bone marrow suppression, gastrointestinal toxicity (i.e. nausea, vomiting, diarrhea, and stomatitis) and pulmonary toxicity.
What if I miss a dose?
If you miss a dose of medication, try to take it as soon as possible. However, if it is almost time for your next dose, take only that scheduled dose. Do not take double or extra doses.
How should I store this medication?
Keep out of the reach of children at all times. Store at room temperature, 59 to 86° F (15 to 30° C). Protect from light. Keep the container tightly closed. Properly dispose of any unused medication after the expiration date.
What are the possible side effects of using this medication?
Palbociclib, Ibrance fatigue, alopecia, skin rash, xeroderma, nausea, stomatitis, diarrhea, elevated liver enzymes, infection, asthenia, fever.
Note this is not a complete list of side effects, only common ones.
- Choosing a selection results in a full page refresh.
- Press the space key then arrow keys to make a selection.